NCT02135874 2024-03-22
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
29 trialsNCT02728050 2023-07-05
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
University of Washington
Phase 1/2 Completed
NCT01253070 2022-08-04
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT04788420 2022-06-01
Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML
Nanfang Hospital, Southern Medical University
Completed
NCT01445080 2021-02-02
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02779283 2020-05-26
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 1 Completed
NCT02530476 2020-03-31
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03170895 2020-03-30
Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD
The University of Hong Kong
Phase 2 Completed
NCT02196857 2020-01-14
Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02474290 2019-08-26
Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML
Nanfang Hospital, Southern Medical University
Phase 2/3 Completed
NCT00474929 2019-08-20
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT00542971 2018-08-23
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01534260 2018-08-17
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
Indiana University
Phase 1/2 Completed
NCT00908167 2018-01-12
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02270788 2017-10-03
Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00943943 2017-03-29
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01398501 2017-03-22
Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant
Massachusetts General Hospital
Phase 1 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01576185 2016-05-17
Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia
Children's Oncology Group
Completed
NCT01254890 2016-05-06
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00893373 2016-02-05
SORAML
Technische Universität Dresden
Phase 2 Completed
NCT00131937 2015-09-03
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00665990 2015-01-09
Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00661180 2014-12-23
ORACLE
Bayer
Phase 2 Completed
NCT00875745 2014-09-18
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Indiana University
Phase 1 Completed
NCT00303797 2013-03-19
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00131989 2013-01-09
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00118170 2013-01-07
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
National Cancer Institute (NCI)
Phase 1 Completed
NCT00373373 2009-08-19
Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
University Hospital Muenster
Phase 2 Completed